All In Biotech

NDA 208587 · Emmaus Medcl

Endari

L-Glutamine · Oral · Amino Acid

Orphan

Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jul 7, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

150

32 Phase 3, 9 recruiting

FAERS reports

4,606

2,873 serious, 128 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 20, 2025.

Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. ENDARI is an amino acid indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. ( 1 )

Mechanism: The mechanism of action of the amino acid L-glutamine in treating sickle cell disease (SCD) is not fully understood. Oxidative stress phenomena are involved in the pathophysiology of SCD. Sickle red blood cells (RBCs) are more susceptible to oxidative damage than normal RBCs, which may contribute to the chronic hemolysis and vaso-occlusive events associated with SCD. The pyridine nucleotides, NAD + and its reduced form NADH, play roles in regulating and preventing oxidative damage in RBCs. L-glutamine may improve the NAD redox potential in sickle RBCs through increasing the availability of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 7, 2017 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
  • ENDARI · L-GLUTAMINE 5GM/PACKET · FOR SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "L-Glutamine" as an intervention, any sponsor and status, largest first.

All 150 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • sickle cell anaemia with crisis1,751
  • product dose omission issue723
  • pain281
  • product dose omission272
  • nausea241
  • headache214
  • hospitalisation212
  • diarrhoea201
  • abdominal pain upper160
  • constipation152
  • fatigue150
  • drug dose omission132

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200518
20066
20077
200810
20097
201018
201117
201232
201322
201428
201547
201688
201796
2018781
2019608
2020439
2021260
2022352
2023456
2024707
2025361
2026232

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Endari (Glutamine)

2024 spending

$5.3M

Beneficiaries

490

1,638 claims

Per beneficiary

$10,868

$22.25 per unit

View as table
YearSpending
2020$7,343,530
2021$6,651,056
2022$6,571,999
2023$8,272,577
2024$5,325,108

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 172 on PubMed

Sponsor: Emmaus Medcl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.